Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3

Status

Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Non-Small-Cell Lung 8Advanced Solid Tumor 7Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Colorectal Neoplasms 5Stomach Neoplasms 4Melanoma 4Carcinoma, Hepatocellular 4Solid Tumor 3Solid Tumors 2Lymphoma 2Head and Neck Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Germ Cell Tumor 1Skin Neoplasms 1Simpson-Golabi-Behmel syndrome 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neuroendocrine Tumors 1Neoplasms 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Cancer 1

Interventions

pembrolizumab 10Docetaxel 8senaparib 7Injections 7Capecitabine 7Paclitaxel 6Cisplatin 6Irinotecan 5Fluorouracil 5Leucovorin 4Cyclophosphamide 4Bevacizumab 4tislelizumab 3pertuzumab 3fludarabine 3atezolizumab 3Rifampin 3Oxaliplatin 3Itraconazole 3Gemcitabine 3ontuxizumab 2navoximod 2fluzoparib 2durvalumab 2Trastuzumab 2Nivolumab 2Midazolam 2Hydroxychloroquine 2Carboplatin 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumor × tislelizumab × Clear all
NCT06487858 2026-05-11

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

BeOne Medicines

Phase 1 Terminated
42 enrolled
Other solid neoplasm

Solid Tumor

NCT06349837 2026-05-01

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Sichuan University

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

NCT05494762 2025-05-01

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Terminated
55 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡